Macrophage phagocytosis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major effector mechanism in xenograft models. Here, using syngeneic immunocompetent mouse tumor models, we reveal that the therapeutic effects of CD47 blockade depend on dendritic cell but not macrophage cross-priming of T cell responses. The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice. In addition, the antitumor effects of CD47 blockade required expression of the cytosolic DNA sensor STING, but neither MyD88 nor TRIF, in CD11c + cells, suggesting that cytosolic sensing of DNA from tumor cells is enhanced by anti-CD47 treatment, further bridging the innate and adaptive responses. Notably, the timing of administration of standard chemotherapy markedly impacted the induction of antitumor T cell responses by CD47 blockade. Together, our findings indicate that CD47 blockade drives T cell-mediated elimination of immunogenic tumors.
Phagocytosis relies on a balance between prophagocytic ("eat me") and antiphagocytic ("don't eat me") signals on target cells [1] [2] [3] . CD47, initially observed on stem cells, is a transmembrane protein that inhibits phagocytosis by binding to its receptor, signal regulatory protein α (SIRPα), which is expressed on phagocytes [4] [5] [6] . Lack of CD47 on erythrocytes, platelets and lymphohematopoetic cells results in rapid clearance of these cells by macrophages, due to elimination of the CD47-SIRPα-mediated antiphagocytic signal 4, 5, 7, 8 . Binding of CD47 to SIRPα results in phosphorylation of immunoreceptor tyrosinebased inhibitory motifs (ITIMs) on SIRPα and recruitment of Src homology phosphatases 1 and 2 (SHP-1 and SHP-2), both of which inhibit accumulation of myosin-IIA at the phagocytic synapse 9 .
Abundant CD47 expression has also been observed on a variety of malignant cells, including both hematopoietic and solid tumors, especially tumor-initiating cells, where elevated CD47 expression has predicted poor survival in individuals with cancer [10] [11] [12] [13] [14] . These data provide a strong rationale for therapeutic targeting of CD47 (refs. 12,15) . Human CD47-blocking monoclonal antibodies (mAbs) have demonstrated efficacy in various preclinical models of human lymphoma, bladder cancer, colon cancer, glioblastoma, breast cancer, acute lymphocytic leukemia and acute myeloid leukemia 11, 12, [16] [17] [18] . Most work concluded that the therapeutic effects of anti-human CD47 were macrophage dependent. However, these studies employed xenografted human tumors in T cell-deficient mice 16, 18, 19 . Thus, they were not able to evaluate the role of adaptive immunity in the effectiveness of CD47 blockade. A previous study showed that morpholino-mediated knockdown of CD47 on tumors in wild-type (WT) mice enhanced the tumoricidal activity of CD8 + T cells when combined with irradiation 20 . But irradiation alone is known to stimulate antitumor CD8 + T cell responses 21 . Therefore, it remains unclear how CD47 knockdown or antibody-mediated blockade alone controls tumor growth in an immunocompetent host harboring a syngeneic tumor.
Here we show that the therapeutic effect of CD47 blockade in syngeneic tumor models largely depends on the activation of T cells. More specifically, we demonstrate that the therapeutic effects of anti-CD47 relies on a cytosolic DNA sensor, dendritic cells (DCs), type I/II interferons (IFNs) and CD8 + T cells. As such, we conclude that anti-CD47-mediated tumor rejection requires both innate and adaptive immune responses.
RESULTS T cells are essential for anti-CD47-mediated tumor regression
To evaluate whether treatment with an anti-mouse-CD47 mAb (anti-CD47: MIAP301), known to functionally inhibit CD47-SIRPα interactions, could reduce tumor burden in syngeneic WT mice, we subcutaneously (s.c.) inoculated BALB/c mice with CD47 + A20 B cell lymphoma cells. Seven days later, we administered anti-CD47 intraperitoneally (i.p.) and monitored tumor growth. Compared to isotype control antibody treatment, systemic anti-CD47 treatment slowed the growth of tumor and prolonged the survival of mice bearing immunogenic A20 tumors ( Fig. 1a and Supplementary Fig. 1a ). To extend these findings to a solid tumor model, we treated syngeneic C57BL/6 mice bearing established MC38 tumors in a similar manner and observed similar results ( Supplementary Fig. 1b,c) . To focus on the effect of anti-CD47 within the tumor microenvironment and rule out any effect on peripheral tissues, we administered anti-CD47 by intratumoral injection in both the A20 and MC38 models ( Fig. 1b,c) . After only two low doses of anti-CD47, established tumors completely regressed. Because anti-CD47 might have offtarget effects 22 , we employed a high-affinity Sirpα variant human Fc fusion protein (SIRPα-hIg) as a second approach to antagonize CD47-SIRPα interactions in vivo 23 . Consistently, intratumoral blockade of CD47-SIPRα interactions via this approach recapitulated the inhibition of A20 tumor growth triggered by antibody-mediated CD47 blockade ( Fig. 1d) .
We next addressed the extent to which the antitumor effect of CD47 blockade depended on host T cells. Thus, we inoculated A20 lymphoma cells s.c. into syngenic BALB/c nude mice. The same short course of intratumoral anti-CD47 treatment that was efficacious in WT BALB/c mice had no effect on tumor growth in T celldeficient nude mice ( Fig. 1e) . Although a longer course of consecutive intratumoral anti-CD47 administrations resulted in a transient suppression of tumor growth in tumor-bearing nude mice ( Fig. 1f) , T cells were clearly required for a maximal therapeutic effect of CD47 blockade therapy.
To understand which T cell subsets were involved in anti-CD47mediated tumor reduction, we treated WT mice bearing established A20 tumors with anti-CD47 intratumorally in conjunction with CD8 + or CD4 + T cell depletion achieved by intraperitoneal delivery of anti-CD4 or anti-CD8 mAbs. In the absence of CD8 + T cells, the therapeutic effect of anti-CD47 was completely abrogated, whereas depletion of CD4 + T cells had no effect ( Fig. 2a) . CD8 + or CD4 + T cells were also depleted in mice systemically treated with anti-CD47. These tumors grew faster in the absence of CD8 + T cells, indicating that this T cell subset is required for tumor regression also following systemic CD47 blockade ( Supplementary Fig. 2a,b) .
To determine whether the immune response initiated by anti-CD47 treatment resulted in T cell-mediated memory response against tumor antigens, we rechallenged mice that had rejected A20 lymphomas after an initial course of CD47 blockade (tumor-free >30 days) with a higher dose of A20 cells (2.5 × 10 7 cells) in the contralateral flank. Compared to naive mice, in which a primary A20 cell challenge resulted in rapid tumor progression, those that had rejected an initial tumor challenge after CD47 blockade were completely resistant to a rechallenge with A20 cells (Fig. 2b) . These results clearly demonstrate that anti-CD47 treatment can elicit durable systemic immune memory to prevent relapse.
To determine whether anti-CD47 treatment can enhance tumor antigen-specific T cell responses, we treated mice harboring established ovalbumin (OVA)-expressing MC38 tumors with anti-CD47 or isotype control antibody intratumorally. Five days after CD47 blockade, we re-stimulated cells from the tumor-draining lymph node in vitro with or without the OVA-derived SIINFEKL peptide and measured IFN-γ production by enzyme-linked immunospot (ELISPOT) assay. Significantly more IFN-γ spot-forming cells were present in the anti-CD47-treated versus the isotype control antibody-treated group (Fig. 2c) . We observed similar results in the A20 model, where we used irradiated A20 cells to re-stimulate tumor-draining lymph node cells in vitro ( Fig. 2d) . To determine whether IFN-γ was essential for the therapeutic effect of anti-CD47, we treated mice bearing A20 tumors with IFN-γ-blocking antibodies on the day of anti-CD47 treatment. The therapeutic effect of anti-CD47 was completely lost in IFN-γ-deficient mice ( Fig. 2e) . Collectively, these data suggest that an antigen-specific T cell response is enhanced after anti-CD47 treatment for both carcinoma and lymphoma tumor types.
Anti-CD47 enhances DC cross-priming for tumor control
A recent study demonstrated that macrophages, and not DCs, were the major antigen-presenting cells (APCs) that cross-prime CD8 + T cells after CD47 blockade in an in vitro xenoculture system 24 . To verify these results, we used an in vitro syngeneic culture system in which both bone marrow-derived macrophages (BMDMs) and bone marrow-derived DCs (BMDCs) were probed for their ability to cross-prime CD8 + T cells in the presence or absence of anti-CD47. npg Whereas anti-CD47 did not significantly increase the cross-priming abilities of BMDMs, BMDCs were able to cross-prime CD8 + T cells to a greater extent than BMDMs in general, but particularly in the presence of anti-CD47 ( Fig. 3a) .
To evaluate the cross-priming capacity of DC and macrophages in response to anti-CD47 in vivo, we collected DCs and macrophages from either the MC38 tumor microenvironment or draining lymph nodes (DLN) of anti-CD47-treated MC38-OTIp-bearing mice and cocultured them with OVA-specific OTI T cells. DCs and macrophages were isolated by FACS, and their purity was validated by quantitative RT-PCR using the lineage-defining transcription factor genes Mafb (macrophages) and Zbtb46 (DCs) ( Supplementary  Fig. 3a ). We hypothesized that anti-CD47 would increase phagocytosis inside the tumor, leading to migration of antigen-loaded APCs to the DLN, where they would fully mature and cross-prime naive T cells. However, we did not observe significant cross-priming by either macrophages or DCs from the DLN from anti-CD47-treated mice (Fig. 3b) . In contrast, primary DCs, but not macrophages, harvested from the tumor microenvironment clearly elicited increased activation of T cells after anti-CD47 treatment (Fig. 3c) . We observed similar effects using macrophages and DCs from mice bearing A20-HA (hemagglutinin expressing) lymphomas after coculture with HA-reactive T cells from CL4 T cell receptor (TCR)-transgenic (Tg) mice, in which the TCR is specific for the HA antigen. We observed augmented T cell cross-priming induced by DCs compared to macrophages, suggesting that anti-CD47 therapy enhances the ability of DCs (but not macrophages) to cross-prime T cells across tumor subtypes ( Supplementary Fig. 4a ). This was also the case when we analyzed parental A20 or MC38 tumors, indicating that DC-mediated cross-priming of T cells specific for naturally expressed tumor antigens was also enhanced following anti-CD47 therapy ( Fig. 3d,e ). To assess whether anti-CD47 had a similar impact in an orthotopic tumor model, we implanted TUBO, an oncogenic receptor neu + mammary tumor, into mammary fat pads of neu-transgenic mice, f Figure 3 Anti-CD47 triggers the cross-priming ability of DCs. (a) BMDCs or bone marrow macrophages were cultured with MC38-OTIp in the presence of fresh granulocyte-macrophage colony-stimulating factor (GM-CSF) and anti-CD47 overnight. Subsequently, purified CD11c + cells or F4/80 + cells were cocultured with isolated CD8 + T cells from naive OTI mice for 3 d and analyzed by IFN-γ cytometric bead array (CBA). (b,c) MC38-OTIp-bearing mice (n = 5 per group) were treated twice with 50 µg of either anti-CD47 or ratIg on days 11 and 14 intratumorally. Five days after the initial treatment, DLN DCs (b) and tumor-infiltrating (c) DCs and macrophages were isolated and cocultured with isolated CD8 + T cells from naive OTI mice for 3 d. IFN-γ production was detected by CBA. (d,e) A20 (d) or MC38 (e) tumor-bearing C57BL/6 mice (n = 5 per group) were treated with 50 µg of either anti-CD47 or ratIg isotype control on day 10. Four days after the antibody treatment, 3 × 10 4 tumor-infiltrating DCs and macrophages were isolated and cocultured with isolated 3 × 10 5 CD8 + T cells from A20 (d) or MC38 (e) tumor-bearing mice. Forty-eight hours later, IFN-γ-producing cells were enumerated by ELISPOT assay. (f) Five weeks after the indicated CD11c-DTR bone marrow chimera reconstitution, C57BL/6 mice (n = 5 per group) were injected s.c. with 1 × 10 6 MC38 cells and treated with 50 µg of anti-CD47 or ratIg on days 14 and 20 (indicated by black arrow). Diphtheria toxin or PBS was administrated on the same day as treatment. Data are reported as the means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student's t-test). One representative experiment out of three independent experiments is depicted.
which we subsequently treated with anti-CD47 or isotype control mAb. Here again, increased T cell cross-priming by DCs was observed when they were cocultured with CD8 + T cells isolated from TUBO tumor-bearing mice (Supplementary Fig. 4b ). Together, these findings indicate that anti-CD47 therapy enhances cross-priming of antigen-specific T cells by tumor-resident DCs.
To determine whether anti-CD47-induced DC activation was also required for tumor control, we inoculated tumor-bearing CD11cdiphtheria toxin receptor (Itgax-DTR) bone marrow-chimeric (BMC) mice with MC38 cells s.c. and treated them with diphtheria toxin (DT) to deplete DCs during anti-CD47 treatment. The therapeutic effect of CD47 blockade was severely impaired following DC depletion in tumor-bearing mice (Fig. 3f) . However, selective removal of tumor-associated macrophages by a colony-stimulating factor (CSF1)blocking mAb had no impact on the antitumor response following CD47 blockade (Supplementary Fig. 3b ). These data strongly suggest that increased DC cross-priming of cytotoxic T lymphocytes is crucial for the therapeutic effect of anti-CD47 treatment.
Requirement for DC responsiveness to type I IFNs for tumor control Type I IFNs are known to increase the cross-priming capability of DCs after various antitumor therapies [25] [26] [27] [28] [29] . Therefore, we investigated whether type I IFNs were involved in cross-priming induced by CD47 blockade. First, mice with established MC38 tumors were treated with anti-CD47 or isotype control rat Ig. Subsequently, DCs and macrophages were sorted from tumor tissues, and levels of type I IFN mRNA (Ifna and Ifnb) were determined by quantitative PCR. DCs from mice treated with anti-CD47 expressed more Ifna mRNA than DCs from mice treated with rat immunoglobulin (Ig) isotype control. In contrast, anti-CD47 boosted Ifna mRNA abundance in the monocyte and macrophage population by only twofold (Fig. 4a) . Similar patterns were observed for Ifnb mRNA (Fig. 4a) .
To test whether type I IFNs were required for the anti-CD47 mediated antitumor effect in vivo, mice bearing MC38 or A20 tumors were treated with intratumoral injections of IFNAR-blocking antibody on days 0 and 2 after injection with anti-CD47 or isotype control. Blocking type I IFN signaling impaired the therapeutic effect of anti-CD47 ( Fig. 4b and Supplementary Fig. 5) , suggesting that type I IFNs are essential for anti-CD47-mediated tumor regression. Given the important role of type I IFNs on DC activation and the importance of DCs in anti-CD47-mediated therapeutic effects, we assessed whether type I IFN signaling specifically in DCs was required for tumor responses following CD47 blockade. To this end, we established MC38 tumors in CD11cCre + ; Ifnar1 fl/fl mice and Ifnar1 fl/fl mice. Conditional deletion of Ifnar1 in CD11c + cells markedly reduced the effect of CD47 blockade on tumor growth ( Fig. 4c) , demonstrating that type I IFN signaling in DCs is necessary for the therapeutic efficacy of anti-CD47. Because CD11c is known to be expressed on cells other than DCs, we performed a DC cross-priming assay using BMDCs. The cross-priming capacity of BMDCs from Ifnar1-deficient mice in the presence of anti-CD47 was compromised compared to that of BMDCs from wild-type mice (Fig. 4d) . Together, these data indicate that type I IFN signaling in DCs plays an integral role in boosting the adaptive immune response to anti-CD47 antibody therapy.
Essential role for cytosolic DNA sensing for cross-priming Anti-CD47-induced phagocytosis might preferentially target stressed tumor cells expressing high levels of prophagocytic molecules. Substances released by tumor cells engulfed into phagosomes might also promote activation of host APCs [30] [31] [32] . For example, tumor-derived danger-associated molecular patterns (DAMPs) engulfed during phagocytosis could initiate type I IFN production by engaging Toll-like receptor-myeloid differentiation factor-88 (TLR-MyD88) sensing pathways in host APCs 31, 33 . To determine whether host TLR pathways were required for the antitumor effect of anti-CD47 therapy, we established MC38 tumors in Myd88 −/− and Trif −/− (Trif is officially known as Ticam1) mice. The inhibition of tumor growth after anti-CD47 treatment was comparable in WT, Myd88 −/− and Trif −/− mice (Fig. 5a,b) , indicating that TLR signaling in host cells is dispensable for the antitumor effect of CD47 blockade. These results also suggest that anti-CD47 activates cross-priming through a TLR-independent pathway.
Recent studies have revealed a cytosolic DNA-sensing pathway involving the endoplasmic reticulum-resident protein stimulator of interferon genes (STING) [34] [35] [36] [37] [38] . The STING pathway is also essential for host DC sensing of tumor DNA 39, 40 . To determine the role of STING in anti-CD47-mediated antitumor responses, we implanted MC38 tumor cells in flanks of WT and Tmem173 gt (STING-deficient) mice and monitored tumor growth after treatment with anti-CD47 or isotype control rat Ig. Tumor growth was identical in WT mice treated with isotype-control rat Ig and in Tmem173 gt mice treated with isotype control rat Ig. However, the antitumor effects of anti-CD47 treatment were completely abrogated in Tmem173 gt mice compared with WT mice (Fig. 5c) . Thus, cytosolic DNA sensing through STING is absolutely essential for the antitumor effect of anti-CD47 therapy.
To evaluate whether STING was essential for induction of type I IFN after anti-CD47 therapy, we treated WT or Tmem173 gt mice bearing MC38 tumors with anti-CD47. Five days later, we measured Ifna mRNA expression levels in tumor-infiltrating DCs. We observed a significant induction of Ifna transcripts in DCs from WT but not Tmem173 gt mice following CD47 blockade (Fig. 5d) . To determine whether the anti-CD47-induced DC cross-priming of CD8 + T cells depends on STING, we conducted a cross-priming assay with BMDCs from WT and Tmem173 gt mice. The cross-priming capacity of WT but not Tmem173 gt DCs was significantly increased by coculture with tumor cells and anti-CD47 (Fig. 5e) . We reached a similar conclusion by IFN-γ ELISPOT assay of purified CD8 + T cells from tumor DLNs of WT and Tmem173 gt mice treated with anti-CD47; anti-CD47 induced tumor-specific CD8 + T cell IFN-γ production in WT but not Tmem173 gt mice (Fig. 5f) . Overall, these results suggest that the STING-dependent cytosolic DNA sensing pathway is essential for anti-CD47-induced antitumor adaptive immune responses.
Chemotherapy influences anti-CD47 effects
Clinical trials of anti-CD47 treatment are underway, but many patients might also have received or continue to receive chemotherapy. As our data reveal an essential role of T cells, and as chemotherapy can suppress d npg the immune system and kill recently activated immune cells 41, 42 , chemotherapy may blunt the therapeutic effects of anti-CD47 antibody therapy. Alternatively, chemotherapy may synergize with anti-CD47 by increasing release of antigens and DNA from dying tumor cells.
To test whether chemotherapy drugs used for lymphoma synergize with or inhibit anti-CD47 therapy, we combined anti-CD47 treatment with clinically equivalent doses of cyclophosphamide (CTX) or paclitaxel (PTX) to treat large, established A20 tumors in BALB/c mice. PTX (40 mg/kg) or CTX (60 mg/kg) was administered 3 days before or after anti-CD47 treatment. Chemotherapy administered after anti-CD47 treatment did not result in faster tumor regression than anti-CD47 alone (Fig. 6a,b) . To test the impact of chemotherapy on anti-CD47-mediated acute and memory immune responses, all tumors were surgically removed. One week after surgery, mice were rechallenged with 1.5 × 10 7 A20 cells. All mice whose primary tumor underwent anti-CD47 treatment alone rejected the tumor rechallenge ( Fig. 6c) . In contrast, a majority of the mice treated with anti-CD47 followed by chemotherapy were susceptible to tumor outgrowth after rechallenge (50% of CTX combination mice; 80% of PTX combination mice) ( Fig. 6c,d and Supplementary Table 1 ). This suggests that chemotherapy administered after anti-CD47 therapy had detrimental effects on development of beneficial antitumor memory immune responses.
We speculated that there might be a limited window of time when chemotherapy drugs can effectively reduce tumor burden and induce prophagocytic signals without destroying anti-CD47-induced immunity. To test whether chemotherapy given before anti-CD47 also inhibited immune memory, we injected an identical dose of PTX or CTX 1 day before antibody treatment rather than 3 days after. This single treatment of chemotherapy before anti-CD47 not only synergized with anti-CD47 for tumor control but also preserved the host memory response against relapsing tumors generated by anti-CD47 (100% of CTX combination mice and 80% of PTX combination mice resistant to tumor rechallenge) (Fig. 6a-c and Supplementary Table 1 ). Taken together, our results indicate that simple alterations to standard drug administration could have a major impact on primary and memory immune responses to tumors and alter clinical outcomes in response to immunomodulatory anti-CD47 antibody therapy.
DISCUSSION
Previous publications suggested that anti-CD47 therapy exerts antitumor activity by blocking antiphagocytic signaling, leading to tumor cell death by macrophage-mediated phagocytosis in a manner independent of adaptive immunity 12, 16, 18 . In contrast, here we reveal that in immune-competent mice, the therapeutic effect of low doses of anti-CD47 largely depends on DC cross-priming of CD8 + T cells. Within DCs, STING-mediated sensing of DNA, which drives type I IFN production, is also required. Finally, timely combination of conventional therapeutics with immunotherapy can boost the host response to control or even eradicate tumors and prevent future relapse.
Potential reasons for the differences between our conclusions and those of previous studies include differences in the preclinical animal models used 12, 16 . Most previous studies used tumor xenograft models, which are widely used as preclinical models and are an integral part of the US Food and Drug Administration approval process. Anti-human CD47 showed impressive efficacy toward xenografted human tumor cells (especially lymphoma and leukemia) in NSG mice (nonobese diabetic (NOD) severe combined immunodeficiency (SCID) interleukin-2 receptor γ chain-deficient mice without T and B cells) 16, 18 . By comparing syngeneic mouse tumors in WT and T cell-deficient nude mice, we revealed a role for T cells in the therapeutic effects of anti-CD47. Several factors could explain the apparently strong role for phagocytosis observed in xenograft models. First, upon implantation in an NSG model human CD47 binds to NSG mouse SIRPα due to a germline SIRPα mutation of these mice, whereas human CD47 could not bind well to SIRPα in other strains of mice, including BALB/c and C57BL/6 (refs. 43, 44) . This unique binding between human CD47 and NOD mouse SIRPα on activated innate cells makes them more susceptible to antibody blockade. Second, in xenograft models, the therapeutic effect of anti-human CD47 was often achieved at much higher doses (for example, 200 µg daily for consecutive 14 d) than the current study 12 . We did observe better tumor control when a higher dose of anti-mouse CD47 antibody was used in the nude mouse model. Lastly, in a syngeneic setting, anti-CD47 will bind both healthy and malignant cells that express CD47. However, in the xenograft model, only tumor cells express human CD47.
Our work may differ from published works in another way: using an in vitro serum-free assay, a recent study showed that phagocytosis of human tumor cells after anti-human CD47 treatment is mainly attributed to mouse BMDMs, whereas the contribution of BMDCs is almost undetectable 24 . Consistently across multiple experiments, enhancement of cross-priming by macrophages was observed in response to anti-CD47. Conversely, we observed that both BMDCs and primary DCs are more potent than BMDMs and primary macrophages for cross-priming T cells. To explain this contradiction, we have observed that culturing BMDCs without serum results in increased apoptosis and malfunction of the DCs, which could ultimately impair their cross-priming capacity ( Supplementary  Fig. 6 ). Supplemented with serum, BMDCs recovered their ability to cross-prime in vitro. Furthermore, ex vivo-isolated DCs are more able to cross-prime CTL than are ex vivo isolated macrophages after anti-CD47 treatment. Finally, deletion of DCs in vivo limits the antitumor effects of anti-CD47 and the antitumor effect of the anti-CD47 depends on IFNAR on CD11c + cells. Thus, our data clearly demonstrate in an immune-competent syngeneic host that the therapeutic effect of CD47 blockade requires functional DCs.
Another point related to the clinical scenario is tumor immunogenicity. Accumulating evidence suggests that the response to immunotherapies is often reliant on the immunogenicity of a tumor, with tumors bearing high loads of somatic mutations showing greater responsiveness than tumors bearing relatively few somatic mutations. Highly mutated tumors probably express higher numbers of neoantigens that can be better recognized and rejected by host T cells, for example, when the CTLA-4 or PD-1 co-inhibitory pathways are blocked by therapeutic antibodies 45, 46 . As such, it is possible that anti-CD47 treatment could possibly have more impact on immunogenic tumors than on nonimmunogenic tumors.
Finally, standard chemotherapy can have major impacts on anti-CD47 therapy efficacy. Prior studies have shown that chemotherapy can lead to increased expression of cell surface calreticulin on tumor cells 42 . Thus, chemotherapy-mediated upregulation of cell surface calreticulin, a prophagocytic signal, may potentially augment the efficacy of anti-CD47 antibodies by propagating STING signaling. In addition, chemotherapy may lead to increased infiltration of APCs, including DCs and macrophages, to tumor sites 47, 48 . However, properly inducing CD8 + T cell-mediated tumor regression requires careful design of sequence and doses for both chemotherapy drugs and anti-CD47, as inappropriate combination treatments of antibody plus chemotherapy may have negative effects on the host immune npg response to tumor antigens. Thus future clinical trials involving anti-CD47 treatment and standard-of-care chemotherapy must be properly timed and tested, as both synergy and antagonism will be time and dose dependent. In conclusion, understanding the mechanisms by which CD47 blockade interfaces with host antitumor immunity will yield important information for designing new treatments using combinations of anti-CD47 with chemotherapeutics and other immunomodulatory antibodies.
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